Advanced search
Publication Cover
Baylor University Medical Center Proceedings
The peer-reviewed journal of Baylor Scott & White Health
Latest Articles
Submit an article Journal homepage
7
Views
0
CrossRef citations to date
0
Altmetric
Review Article

The efficacy and safety of cabozantinib in patients with metastatic or advanced renal cell carcinoma: a systematic review and meta-analysis

Majd M. AlBarakata Faculty of Medicine, Jordan University of Science and Technology, Irbid, JordanORCID Iconhttps://orcid.org/0000-0002-4676-8942
, MDORCID Icon,
Yaman B. Ahmeda Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan
, MD,
Sakhr Alshwayyata Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan
, MD,
Asmaa Ellaithyb Faculty of Medicine, Suez Canal University, Ismailia, Egypt
, MBBS,
Yaqoub Y. Al-Shammaria Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan
, MD,
Youssef Solimanc Faculty of Medicine, Assiut University, Assiut, Egypt
, MBBCh,
Hazem Rezqd Faculty of Medicine, Al-Azhar University, Cairo, EgyptCorrespondence[email protected]
, MBBCh,
Basel Abdelazeeme Department of Cardiology, West Virginia University, Morgantown, West Virginia, USA
, MD &
Arvind Kunadif Internal Medicine and Nephrology Departments, McLaren Health Care, Flint, Michigan, USA;g Michigan State University, East Lansing, Michigan, USA
, MD show all
Received 30 Mar 2024, Accepted 27 May 2024, Published online: 17 Jun 2024

  • Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol. 2015;67(5):913–924. doi:10.1016/j.eururo.2015.01.005
  • Znaor A, Lortet-Tieulent J, Laversanne M, Jemal A, Bray F. International variations and trends in renal cell carcinoma incidence and mortality. Eur Urol. 2015;67(3):519–530. doi:10.1016/j.eururo.2014.10.002
  • Gupta K, Miller JD, Li JZ, Russell MW, Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review. Cancer Treat Rev. 2008;34(3):193–205. doi:10.1016/j.ctrv.2007.12.001
  • Ko JJ, Choueiri TK, Rini BI, et al. First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. Br J Cancer. 2014;110(8):1917–1922. doi:10.1038/bjc.2014.25
  • Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther. 2011;10(12):2298–2308. doi:10.1158/1535-7163.MCT-11-0264
  • Nickerson ML, Jaeger E, Shi Y, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res. 2008;14(15):4726–4734. doi:10.1158/1078-0432.CCR-07-4921
  • Shen C, Kaelin WG. The VHL/HIF axis in clear cell renal carcinoma. Semin Cancer Biol. 2013;23(1):18–25. doi:10.1016/j.semcancer.2012.06.001
  • Rankin EB, Fuh KC, Castellini L, et al. Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proc Natl Acad Sci USA. 2014;111(37):13373–13378. doi:10.1073/pnas.1404848111
  • Gibney GT, Aziz SA, Camp RL, et al. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann Oncol. 2013;24(2):343–349. doi:10.1093/annonc/mds463
  • Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373(19):1814–1823. doi:10.1056/NEJMoa1510016
  • Choueiri TK, Halabi S, Sanford BL, et al. Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol. 2017;35(6):591–597. doi:10.1200/JCO.2016.70.7398
  • Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639–3646. doi:10.1200/JCO.2012.48.4659
  • Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):917–927. doi:10.1016/S1470-2045(16)30107-3
  • Smith M, De Bono J, Sternberg C, et al. Phase III study of cabozantinib in previously treated metastatic castration-resistant prostate cancer: COMET-1. J Clin Oncol. 2016;34(25):3005–3013. doi:10.1200/JCO.2015.65.5597
  • Belum VR, Serna-Tamayo C, Wu S, Lacouture ME. Incidence and risk of hand-foot skin reaction with cabozantinib, a novel multikinase inhibitor: a meta-analysis. Clin Exp Dermatol. 2016;41(1):8–15. doi:10.1111/ced.12694
  • Pal SK, Tangen C, Thompson IM, et al. A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. Lancet. 2021;397(10275):695–703. doi:10.1016/S0140-6736(21)00152-5
  • Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71
  • Higgins JPT, Thomas J, Chandler J, et al. Cochrane Handbook for Systematic Reviews of Interventions. Wiley; 2019. doi:10.1002/9781119536604
  • Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17(8):2530–2540. doi:10.1200/JCO.1999.17.8.2530
  • Heng DYC, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor–targeted agents: results from a large, multicenter study. J Clin Oncol. 2009;27(34):5794–5799. doi:10.1200/JCO.2008.21.4809
  • Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898
  • Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634. doi:10.1136/bmj.315.7109.629
  • Zhou L, Liu XD, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016;35(21):2687–2697. doi:10.1038/onc.2015.343
  • Gustafsson A, Martuszewska D, Johansson M, et al. Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clin Cancer Res. 2009;15(14):4742–4749. doi:10.1158/1078-0432.CCR-08-2514
  • Harshman LC, Choueiri TK. Targeting the hepatocyte growth factor/c-met signaling pathway in renal cell carcinoma. Cancer J. 2013;19(4):316–323. doi:10.1097/PPO.0b013e31829e3c9a
  • Pinato DJ, Chowdhury S, Stebbing J. TAMing resistance to multi-targeted kinase inhibitors through Axl and Met inhibition. Oncogene. 2016;35(21):2684–2686. doi:10.1038/onc.2015.374
  • Faoro L, Cervantes GM, El-Hashani E, Salgia R. MET receptor tyrosine kinase. J Thorac Oncol. 2009;4(11 Suppl 3):S1064–S1065. doi:10.1097/01.JTO.0000361752.86918.09
  • Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer. 2011;2(12):1097–1105. doi:10.1177/1947601911423031
  • Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23(5):1011–1027. doi:10.1200/JCO.2005.06.081
  • Shojaei F, Lee JH, Simmons BH, et al. HGF/c-met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res. 2010;70(24):10090–10100. doi:10.1158/0008-5472.CAN-10-0489
  • Kwilas AR, Ardiani A, Donahue RN, Aftab DT, Hodge JW. Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine. J Transl Med. 2014;12(1):294. doi:10.1186/s12967-014-0294-y
  • 32nd annual meeting and pre-conference programs of the Society for Immunotherapy of Cancer (SITC 2017): late-breaking abstracts. J Immunother Cancer. 2017;5(S3):89. doi:10.1186/s40425-017-0297-3
  • Escudier B, Tannir NM, McDermott DF, et al. CheckMate 214: efficacy and safety of nivolumab + ipilimumab (N + I) v sunitinib (S) for treatment-naïve advanced or metastatic renal cell carcinoma (mRCC`), including IMDC risk and PD-L1 expression subgroups. Ann Oncol. 2017;28:v621–v622. doi:10.1093/annonc/mdx440.029
  • Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369(8):722–731. doi:10.1056/NEJMoa1303989
  • Chen RC, Choueiri TK, Feuilly M, et al. Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update. Eur J Cancer. 2018;126(24):5311–5318. doi:10.1016/j.ejca.2018.02.012
  • McDermott DF, Lee JL, Ziobro M, et al. Open-label, single-arm, Phase II study of pembrolizumab monotherapy as first-line therapy in patients with advanced non–clear cell renal cell carcinoma. J Clin Oncol. 2021;39(9):1029–1039. doi:10.1200/JCO.20.02365
  • Grünwald V, Lin X, Kalanovic D, Simantov R. Early tumour shrinkage: a tool for the detection of early clinical activity in metastatic renal cell carcinoma. Eur Urol. 2016;70(6):1006–1015. doi:10.1016/j.eururo.2016.05.010
  • Grünwald V, McKay RR, Krajewski KM, et al. Depth of remission is a prognostic factor for survival in patients with metastatic renal cell carcinoma. Eur Urol. 2015;67(5):952–958. doi:10.1016/j.eururo.2014.12.036
  • Duran I, Maroto P, Suárez C, et al. Analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC). JCO. 2019;37(7_suppl):550–550. doi:10.1200/JCO.2019.37.7_suppl.550
  • Powles T, Choueiri TK, Motzer RJ, et al. Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. BMC Cancer. 2021;21(1):904. doi:10.1186/s12885-021-08630-w
  • Facemire CS, Nixon AB, Griffiths R, Hurwitz H, Coffman TM. Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression. Hypertension. 2009;54(3):652–658. doi:10.1161/HYPERTENSIONAHA.109.129973
  • Schmidinger M, Danesi R. Management of adverse events associated with cabozantinib therapy in renal cell carcinoma. Oncologist. 2018;23(3):306–315. doi:10.1634/theoncologist.2017-0335
  • Cappagli V, Moriconi D, Bonadio AG, et al. Proteinuria is a late-onset adverse event in patients treated with cabozantinib. J Endocrinol Invest. 2021;44(1):95–103. doi:10.1007/s40618-020-01272-y
  • Azad NS, Aragon-Ching JB, Dahut WL, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res. 2009;15(4):1411–1416. doi:10.1158/1078-0432.CCR-08-1141
  • Choueiri TK, Powles T, Burotto M, et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2021;384(9):829–841. doi:10.1056/NEJMoa2026982
  • Pal SK, Albiges L, Tomczak P, et al. Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2023;402(10397):185–195. doi:10.1016/S0140-6736(23)00922-4
  • Choueiri TK, Powles T, Albiges L, et al. Cabozantinib plus nivolumab and ipilimumab in renal-cell carcinoma. N Engl J Med. 2023;388(19):1767–1778. doi:10.1056/NEJMoa2212851

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.